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Diane Zimmermann,d Laure Poquet,d Antoine Leveques,d Lucas Actis-Goretta,d
Ian B. Puddeya and Kevin D. Croft*a
Coﬀee is a rich source of polyphenols, primarily chlorogenic acids (CGA). Certain polyphenols and poly-
phenol-rich foods and beverages have been shown to improve endothelial function and lower blood
pressure (BP). The aim of the present study was to investigate the acute eﬀect of two doses of CGA (5-
CGA) on endothelial function and BP. In a cross-over study, 16 healthy men and women received: (i) 0 mg
puriﬁed 5-CGA (control group); (ii) 450 mg puriﬁed 5-CGA; (iii) 900 mg puriﬁed 5-CGA; and (iv) 200 mg
puriﬁed (−)-epicatechin (positive control) in random order one week apart. Peak and continuous mean
(60 to 240 s post ischaemia) ﬂow-mediated dilation (FMD) was measured at baseline, 1 h and 4 h. BP was
measured at baseline and every 30 min to 4 h. Plasma CGA and epicatechin levels were signiﬁcantly
increased at both 1 h and 4 h post their respective treatments. Peak FMD was not signiﬁcantly altered by
either dose of 5-CGA or the epicatechin, relative to control (p > 0.05). Relative to control, eﬀects on con-
tinuous mean FMD response following 450 mg 5-CGA and 900 mg of 5-CGA (0.47 ± 0.16%, p = 0.016
and 0.65 ± 0.16%, p < 0.001, respectively) at 1 h and (0.18 ± 0.17%, p = 0.99 and 0.44 ± 0.16%, p < 0.05,
respectively) at 4 h. There was no signiﬁcant eﬀect of any of the treatments on BP. In conclusion, the
present study has found no signiﬁcant eﬀect of 5-CGA, at 450 and 900 mg, on peak FMD response.
However, there were signiﬁcant improvements in mean post-ischaemic FMD response, particularly at the
1 h time point in this group of healthy individuals.
Introduction
Dietary patterns characterised by high intake of fruits and veg-
etables are consistently associated with lower risk of chronic
diseases, including cardiovascular disease (CVD). These bene-
ficial eﬀects are thought to arise from the abundance of nutri-
ents and phytochemicals, including polyphenolic compounds,
found in fruits and vegetables.1 An important mechanism in
the protection against CVD by these plant polyphenols is
thought to be via lowering of blood pressure (BP) and improve-
ments in endothelial function through changes in nitric oxide
(NO). NO is an important signalling molecule that is essential
for the normal function of blood vessels. There is consistent
evidence that certain polyphenols can improve endothelial
function and lower blood pressure (BP) through eﬀects on NO
metabolism.2
Coﬀee is one of the most widely consumed beverages in the
world and represents an important dietary source of polyphe-
nolic compounds. The major polyphenolic compounds found
in coﬀee are chlorogenic acids (CGA), which represents ∼86%
of total polyphenol content. Coﬀee drinkers can have a daily
intake of 0.5–1 g per day of CGA, while abstainers typically
consume <100 mg per day.3 While the predominant isomer
found in coﬀee is 5-CGA, the actual amount and composition
of coﬀee polyphenols can be aﬀected by brewing methods.4
Epidemiological studies, and meta-analysis derived from these
studies, have suggested that moderate coﬀee consumption
(3–4 cups per day) is associated with beneficial eﬀects on a
range of chronic diseases, including CVD and type 2
diabetes.5–7
Several other plant-based polyphenols have been shown to
have beneficial eﬀects on NO status and endothelial function.
Loke et al. demonstrated that pure quercetin and epicatechin,
polyphenols found in fruits, cocoa and tea, significantly
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increased NO status 2 h after ingestion.8 Schroeter et al.
observed beneficial eﬀects on endothelial function following
ingestion of pure epicatechin.9 Studies looking specifically at
CGA are limited. A recent acute study demonstrated a
reduction in BP 1 h post ingestion of 400 mg of CGA (3-CQA,
Sigma Aldrich). There were no significant eﬀects on endo-
thelial function or NO production.10
The timing of the measurements, along with the dose of
polyphenols given are important considerations. Following
ingestion of CGA, peak circulating concentrations of CGA are
reached at approximately 1 hour, and CGA metabolites begin
to appear in the circulation from approximately 3–4 hours.11
With this in mind, the aim of the present study was to investi-
gate the eﬀect of a 450 mg and a 900 mg dose 5-CGA on endo-
thelial function and BP. The doses were chosen to represent
the CGAs present in 4 and 8 cups (approx. 111 mg per cup) of
coﬀee respectively.12 Endothelial function measurements were
taken at baseline and 1 h and 4 h post-treatment to coincide
with peak plasma concentrations.11 BP was measured at base-
line and then every 30 min post-treatment. Participants were
selected based on an impaired endothelial function (a screen-
ing peak flow-mediated dilatation (FMD) response between
3–8%), but were otherwise healthy. The primary outcome of
this study was peak FMD response. The major secondary out-
comes were the continuous mean FMD response between 60
to 240 s post-ischaemia, which represents a continuous vascu-
lar dilatory response to ischaemia, and clinic BP.
Methods
Study design
This was a double-blind, randomised, placebo controlled
cross-over trial. Sixteen healthy men (n = 6) and women (n =
10) were recruited to the School of Medicine and Pharma-
cology, Research Studies Unit (Fig. 1). All participants were
aged between 18 and 70 years of age and were regular consu-
mers of coﬀee. Following an informed consent, participants
underwent assessment of their flow-mediated dilatation
(FMD). Those with an FMD between 3 and 8% at screening
were included into the study. Additional exclusion criteria
included; smokers, known food allergies, systolic BP <100 or
>160 mmHg and diastolic BP <50 or >100 mmHg, pregnant or
lactating women, use of antihypertensive medication, elevated
cholesterol or use of cholesterol-lowering medication, recent
significant weight loss or gain (>6% of body weight), BMI
outside 18–35 kg m−2 range, or presence of major chronic
illness.
All participants were advised not to consume more than 2
pieces of fruit, red wine or dark chocolate in the 24 h period
prior to their study visit. Tea and coﬀee consumption was not
permitted 12 h prior to their study visit. On the morning of
their study visit, all participants consumed a standardised
breakfast (2 pieces of white bread with cheese, tub of plain
yoghurt and water), approximately 2 h prior to their visit. Par-
ticipants then underwent a baseline FMD assessment of their
brachial artery, BP measurement and provided a blood
sample. They were allocated to receive the study treatments in
random order via computer generated block randomisation.
Both the participants and the study personnel were blinded to
the treatments for the duration of the study and subsequent
analysis. Treatments were as follows; (i) 1 g maltodextrin
(control group), (ii) 450 mg purified 5-CGA + 1 g maltodextrin,
(iii) 900 mg purified 5-CGA + 1 g maltodextrin, or (iv) 200 mg
purified (−)-epicatechin + 1 g maltodextrin (positive control).
Treatments were given dissolved in 200 mL of warm water and
consumed within 10 minutes, with a minimum one-week
Fig. 1 Study recruitment and enrolment ﬂow chart.
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washout between visits. At 1 h and 4 h post-treatment, partici-
pants underwent another FMD assessment and provided a
blood sample. BP was monitored every 30 min from baseline
to 4 h. The study was approved by the University of Western
Australia, Human Research Ethics Committee.
Flow mediated dilatation
Brachial artery vasodilator function was assessed using ultra-
sound according to a previously published protocol.13 A single
trained ultrasonographer performed all measurements. Endo-
thelium-dependent vasodilation was assessed as response to
forearm ischaemic FMD. Briefly, participants rested in a
supine position in a quiet, temperature controlled room (21 °C
to 25 °C). The left arm was comfortably rested on a foam
support and ECG was monitored continuously. A 12-MHz
transducer connected to an Acuson Aspen 128 ultrasound
device (Acuson Corporation) was fixed in position with a
clamp over the brachial artery 5 to 10 cm proximal to the anti-
cubital crease. A baseline artery diameter recording was per-
formed for 1 min. A BP cuﬀ was then placed around the left
forearm and inflated to 200 mmHg for 5 min to induce reac-
tive hyperaemia. The brachial artery image was continuously
recorded for 4 min post cuﬀ deflation to assess FMD. Images
were downloaded for retrospective analysis.
Analysis of scans was performed with semi-automated
edge-detection software.14,15 This automatically calculated the
brachial artery diameter, corresponding to the internal dia-
meter. This was gated to the R wave of ECG, with measure-
ments taken at end diastole. Analysis was performed by an
experienced observer, blinded to the study treatments. Repro-
ducibility studies have previously demonstrated an intra
subject coeﬃcient of variation of 14.7%.15 FMD response was
assessed in two ways. Firstly, as a peak FMD response follow-
ing ischaemia. Secondary analysis was carried out by measur-
ing FMD response every 10 seconds from 60 s (average time to
peak dilatation post-ischemia), to 4 min (240 s) post cuﬀ defla-
tion as a measure of continuous post-ischaemic FMD
response. This outlined us the opportunity to detect smaller
diﬀerences following the CGA treatments. The FMD response
provides a guide to NO-mediated endothelial cell function.16
Blood pressure assessment
Clinic blood pressure was monitored every 30 min using a
Dinamap 1846SX/P oscillometric recorder (Critikon, Tampa,
FL, USA). Subjects were rested for 3 min in a sitting position. A
cuﬀ was fitted to the right arm and 3 readings were taken,
1 min apart. The first reading was discarded and the second
and third averaged to give a final BP. The BP data were ana-
lysed at each of the time points and as an overall 4 h diﬀerence
between treatment groups.
Plasma nitrite concentrations
Plasma nitrite concentration, as a reflection of overall nitric
oxide status, was measured on freshly isolated plasma using
gas phase chemiluminescence. Briefly, blood was collected
into N-ethylmaleimide (10 mmol L−1) and EDTA (2 mM),
mixed and centrifuged immediately at 3000 rpm, for 5 min at
4 °C. Plasma was isolated, kept on ice in the dark and analysed
within 1 h of collection. For determination of nitroso species,
fresh plasma (300 μl) was treated with sulphanilamide solution
(30 μl, 0.5% in 0.1 M HCl) for 3 min to remove the endogenous
nitrite. Antifoam (200 μl) was added prior to injection into the
radical purger containing potassium iodide (0.125 g) and
iodine (0.05 g) in water (2.5 mL)/glacial acetic acid (7.5 mL) at
room temperature. Plasma S-nitrosothiols (+nitrosylated
species) are quantified by the NO signal peak area of samples
pre-treated with sulphanilamide against a nitrite standard
(300 μl, 0.5 μM NaNO2−). Quantification of NO released by the
redox reactions occurs by its chemiluminescence reaction with
ozone using a Nitric Oxide Analyser (CLD66, Eco Physics,
Sweden).
Plasma CGA concentrations
Plasma polyphenol concentration was measured on stored
plasma samples by liquid chromatography mass spectrometry,
at the Nestle Research Centre following completion of the
study. Briefly, to 380 μl of plasma, 20 μl of internal standard
(3-(4-hydroxyphenyl)-propionic acid) was added, mixed and
placed at 4 °C. The sample was then injected into the Trans-
cend turbulent flow chromatography system (Thermo Fisher
Scientific) coupled to a 3200 Q TRAP mass spectrometer
instrument equipped with a Turbo Ion Spray ionisation source
(Applied Biosystems, Foster City, USA). Blank samples spiked
with known concentrations of standard were used to quantify
plasma concentrations.17
Statistical analysis
Statistical analysis was carried out using IBM SPSS Statistics
Version 21 (2012, Armonk, NY: IBM Corp) and STATA (version
13 StataCorp LP, College Station, TX). All analysis was per-
formed with intention to treat. That is, all participants ran-
domised to the study were included in the final analysis,
regardless of whether they completed all four study treatments
or followed the recommended diet. Each analysis was per-
formed using a mixed eﬀects regression model to account for
the cross-over design with repeated measurements both within
and across visits. The model for FMD included fixed eﬀect
terms for treatment, visit (1, 2, 3 or 4), scan (baseline, 1 hour
or 4 hours), time point (60 to 240 seconds in categories of 10
seconds), as well as an interaction term between treatment
and scan. Since there was a significant interaction between
treatment and scan, we stratified the remaining analysis by
scan using the same model for each scan but excluding the
scan X treatment interaction term. The participant ID number
was included as a random intercept in each model.
The p values for the estimated treatment eﬀects were Bonfer-
roni adjusted to account for the 6 multiple comparisons
between the 4 treatments. Mean estimated treatment eﬀects
between active treatments and the negative control
were obtained using the estimated marginal means from the
mixed eﬀects model.
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Results
Study participant characteristics
In total, 16 men and women were randomised into the study
with 14 participants completing all four treatments. Their
baseline characteristics are presented in Table 1. The mean
age was 60 years (range: 39–69 years) and the mean screening
FMD was 5.4% (±1.2%).
Eﬀects of 5-CGA on peak FMD response and continuous FMD
response
There was no significant eﬀect on peak FMD response for
either dose of 5-CGA or the epicatechin at 1 h or 4 h post-treat-
ment (Table 2). Secondary analysis of continuous mean post-
ischaemic FMD response following CGA treatment revealed
there was a significant treatment-by-scan interaction
(p<0.001), indicating a diﬀerence in FMD response according
to treatment over the three scans. At 1 h post treatment, there
was a dose-related eﬀect of 5-CGA to increase continuous FMD
response (Fig. 2b). Relative to control, both 450 mg 5-CGA and
900 mg of 5-CGA resulted in a higher continuous FMD
response (0.47 ± 0.16%, p = 0.016; 0.65 ± 0.16%, p < 0.001;
respectively) at 1 h. At 4 h, the only significant diﬀerence
observed was a higher continuous FMD response with 900 mg
5-CGA relative to control (0.44 ± 0.16%, p < 0.05). There was no
significant eﬀect of 450 mg CGA on continuous FMD response
(0.18 ± 0.17%, p = 0.99) (Fig. 2c). There was no significant
eﬀect of epicatechin on mean continuous FMD response (data
not shown).
Eﬀects of 5-CGA on blood pressure
Blood pressure was measured every 30 min from 0 h until 4 h.
At each time point, there was no significant diﬀerence between
the 450 mg and 900 mg 5-CGA groups and control, for systolic
BP or diastolic BP (Table 3). There was no eﬀect of the 200 mg
epicatechin treatment on BP. There was a significant increase
in BP across time, across all four treatments combined.
Eﬀects of 5-CGA on plasma nitrite levels
Circulating plasma nitrite levels were measured as an index of
overall NO production. Relative to control, there was no signifi-
cant eﬀect of 450 mg and 900 mg 5-CGA or 200 mg epicatechin
onplasma nitrite concentrations (Table 4).
Circulating plasma CGA metabolites
The circulating plasma CGA metabolites were measured at
baseline and at 1 h and 4 h to confirm both compliance and
absorbance of the compounds. There were significant
increases in CGA metabolites following their respective treat-
ments at both 1 h and 4 h. Analysis of the individual CGA
metabolites reveals the pattern of metabolism over the 4 h
treatment period and the total phenolic acid profile over the
4 h treatment period (Fig. 3).
Discussion
The present study found no significant eﬀect of 5-CGA on
endothelial function as measured by peak FMD response.
However, we did find a statistically significant dose-related
eﬀect of 5-CGA on continuous mean FMD response. At 1 h,
this improvement was observed for both the 450 mg and
900 mg dose, and this increase was sustained at 4 h for the
900 mg dose. Epicatechin, a dietary flavonoid found in cocoa
and used as a positive control, had no significant eﬀect on
FMD, either measured as peak or continuous response. None
of the polyphenol treatments had any eﬀect on BP.
There is very little work investigating the direct eﬀect of
5-CGA, the major coﬀee polyphenol, on vascular function. A
recent study investigating the acute eﬀect of 400 mg of 3-CGA
Table 1 Study participant characteristics
All participants (N = 16)
Age (years) 59.9 (8.2)
Gender 6 men/10 women
Caucasian 16
Screening FMD (%) 5.4 (1.2)
Height (cm) 168.4 (10.0)
Weight (kg) 70.5 (13.2)
BMI (kg m−2) 24.7 (3.3)
Systolic BP (mmHg) 115.1 (9.1)
Diastolic BP (mmHg) 67.8 (7.4)
Heart rate (bpm) 56.8 (7.4)
Data are presented as mean (SD).
Table 2 Estimated eﬀects of 5-CGA on peak FMD response at 1 hour and 4 hoursa
Time
Estimated diﬀerence
(95% CI) v control
0 h 1 h 4 h 1 h 4 h
Control (n = 14) 6.7 (2.5) 7.1 (3.0) 7.6 (2.5)
450 mg 5-CGA (n = 15) 6.5 (2.1) 7.1 (2.3) 6.9 (3.1) 0.78 (−0.96, 2.52) −0.06 (−1.82, 1.71)
900 mg 5-CGA (n = 14) 6.1 (1.8) 7.2 (2.9) 7.2 (2.6) 0.71 (−1.02, 2.43) 0.22 (−1.55, 1.99)
Epicatechin (n = 15) 6.1 (1.2) 6.8 (2.0) 7.5 (2.8)
Results are presented as mean (SD). a Estimated diﬀerences at 1 hour and 4 hours were obtained from a mixed eﬀects regression model (see stat-
istical methods section for details).
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in healthy subjects demonstrated a reduction in BP at 1 h post
consumption. However, this was not associated with any
improvement in peak FMD response or circulating nitroso/
nitric oxide species.10 In the present study, we used a compar-
able dose of 5-CGA, as well as a higher dose, and measured BP
every 30 minutes and FMD response at both 1 h and 4 h post-
consumption. Although we did not observe any improvement
in BP or peak FMD response, there was a significant dose-
related eﬀect on continuous post-ischaemic FMD response.
Measurement of the continuous FMD dilatory response pro-
vides greater statistical power and allows us to observe smaller,
yet still statistically significant, results. It may also be more
physiologically relevant than measurement of a single time
point peak response, representing a sustained improvement
on vascular function.
The low dose used in the present study corresponds to the
amount of CGA found in approximately 4 cups of regular
roasted coﬀee (or 2 cups of a CGA-enriched coﬀee), while the
high dose corresponds to approximately 8 cups of regular
coﬀee (or 4 cups of a CGA-enriched coﬀee). However, the exact
amount of CGA found in a regular cup of coﬀee can diﬀer
depending on both the type of coﬀee used and the brewing
methods.18 Following ingestion, CGA undergoes extensive
metabolic transformation in both the intestine and colon
before absorption, as well as following absorption in the liver.
As a result, it may be the metabolites of CGA (and other
ingested polyphenols) that have significant biological activity
and subsequent health benefits.2 Although the bioavailability
of these metabolites has been studied, it is likely that this is
also aﬀected by biological and chemical diﬀerences, as well as
individual diﬀerences in enzymatic modification, metabolite
transport and gut microflora.2,4 Although participants were
advised to reduce their polyphenolic intake prior to each study
visit, we cannot rule out the influence of background diet on
both the metabolism of these compounds and their sub-
sequent in vivo eﬀects. As a result, there may be significantly
diﬀerent responses and eﬀects between individuals following
both coﬀee consumption and ingestion of isolated pure poly-
phenolic compounds. The modest increase in continuous
mean FMD response that we observed at 1 h may reflect peak
plasma CGA or metabolite concentrations following transform-
ation of the parent compound. This eﬀect was diminished at
4 h post consumption at the low dose, suggesting the active
metabolites were either excreted, or further metabolised into
inactive compounds.
It is somewhat surprising that epicatechin, our positive
control, had no eﬀect on peak FMD response, particularly
given several other studies have previously demonstrated a
benefit.8,9 The dose used in the present study was similar to
that used in previous studies, and while Loke et al. didn’t
measure FMD response directly, Schroeter et al. measured
response at 2 h post-treatment, although it should be noted
that this was only performed in 3 study participants. It may be
that by measuring FMD response at 1 h and 4 h in the present
study, we have missed the peak beneficial eﬀect of this particu-
lar dietary polyphenol on endothelial function.
There are a number of limitations to consider when inter-
preting the results of the present study. Although the study
was a randomised controlled cross-over study, the number of
participants was small, with 14 completing all four treatment
arms. This limited our power to detect a relatively small
Fig. 2 Observed FMD response between treatments from 0 seconds to
240 seconds post cuﬀ deﬂation at (a) baseline (b) 1 h post-treatment,
and (c) 4 h post-treatment. Estimated eﬀects were obtained using mixed
models with data for 60–240 seconds post cuﬀ-deﬂation.
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change in FMD response. Secondly, it might be that important
time points have been missed in choosing when to measure
FMD response. This is particularly noticeable when consider-
ing the lack of eﬀect seen with epicatechin. The time points
chosen for this study were based on peak times for CGA and
its metabolites. Thirdly, although we recruited participants
based a screening FMD response between 3–8%, they were
considered to be otherwise healthy. This may mean that any
observed benefit of the CGA compounds may have been too
small to detect, as the participants weren’t considered to be a
high-risk group with endothelial dysfunction. Future studies
in populations with existing CVD or pre-existing CVD risk
factors may help to elucidate the beneficial eﬀects of this com-
pound on vascular function. Furthermore, the use of an iso-
lated compound, specifically 5-CGA, may have also limited the
interpretation of our findings. Although it is considered one of
the major polyphenolic compounds in coﬀee, there are many
other compounds present. Use of a single, purified compound
in the present study may have meant that any additive or syner-
gistic eﬀects of other polyphenols also found in coﬀee (par-
ticularly after roasting), could not be observed.
In conclusion, there was no significant eﬀect of 5-CGA or
epicatechin on the peak FMD response, our primary outcome.
We did observe a dose-related improvement in continuous
mean FMD response for 5-CGA at 1 h post ingestion, which
was diminished by 4 h. Future studies examining whole coﬀee,
as well as high-risk population groups, are warranted.
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Results are presented as mean systolic BP/mean diastolic BP (SD).
Table 4 Eﬀects of 5-CGA on plasma nitrite at 1 hour and 4 hours
Nitrate (nM)
0 h 1 h 4 h
Control (n = 14) 131 (98) 237 (229) 205 (97)
450 mg 5-CGA (n = 15) 123 (72) 187 (73) 218 (87)
900 mg 5-CGA (n = 14) 123 (62) 195 (125) 185 (106)
Epicatechin (n = 15) 164 (203) 250 (258) 165 (78)
Results are presented as mean (SD).
Fig. 3 Plasma distribution of CGA metabolites at baseline, 1 h and 4 h
post-treatment.
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